Stock Analysis on Net
Stock Analysis on Net

Biogen Inc. (NASDAQ:BIIB)

$13.99

This company was transferred to the archive: financial data is no longer updated!

Paying users zone. Data is hidden behind: .

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock

This is a one-time payment. There is no automatic renewal.

Biogen Inc. pages available today for free:

Cash Flow Statement

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company’s balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Biogen Inc., consolidated cash flow statement

US$ in thousands

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Net income
Depreciation, amortization and impairments
Acquired in-process research and development
Share-based compensation
Deferred income taxes
Contingent consideration
Loss on divestiture of Hillerød, Denmark manufacturing operations
Other
Accounts receivable
Due from anti-CD20 therapeutic programs
Inventory
Accrued expenses and other current liabilities
Income tax assets and liabilities
Other liabilities
Changes in operating assets and liabilities, net
Adjustments to reconcile net income to net cash flows from operating activities
Net cash flows provided by operating activities
Proceeds from sales and maturities of marketable securities
Purchases of marketable securities
Contingent consideration related to Fumapharm AG acquisition
Acquisition of Nightstar Therapeutics plc, net of cash acquired
Proceeds from divestiture of Hillerød, Denmark manufacturing operations
Acquired in-process research and development
Acquisitions of businesses, net of cash acquired
Purchases of property, plant and equipment
Acquisitions of intangible assets
Purchase of Ionis Pharmaceuticals, Inc. stock
Investment in Samsung Bioepis
Proceeds from sales of strategic investments
Other
Net cash flows (used in) provided by investing activities
Purchase of treasury stock
Net contribution (distribution) to noncontrolling interests
Proceeds from borrowings
Repayments of borrowings
Net cash contribution to Bioverativ, Inc.
Excess tax benefit from share-based compensation
Contingent consideration payments
Other
Net cash flows provided by (used in) financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of the year
Cash and cash equivalents, end of the year

Based on: 10-K (filing date: 2020-02-06), 10-K (filing date: 2019-02-06), 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03).

Cash flow statement item Description The company
Net cash flows provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Biogen Inc.’s net cash flows provided by operating activities increased from 2017 to 2018 and from 2018 to 2019.
Net cash flows (used in) provided by investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Biogen Inc.’s net cash flows (used in) provided by investing activities increased from 2017 to 2018 and from 2018 to 2019.
Net cash flows provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Biogen Inc.’s net cash flows provided by (used in) financing activities decreased from 2017 to 2018 and from 2018 to 2019.